Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) interim results highlight continued progress in its cancer vaccine pipeline, with multiple data readouts expected before the end of 2025, according to Panmure Liberum.
Reiterating its 'buy' advice and 24p a share price target, the brokerage noted that early data releases have helped to reduce some of the risks associated with the programmes.
Panmure Liberum said that following a licence payment from Genmab, a December equity raise, and a larger-than-expected research and development tax credit, Scancell now has sufficient cash to fund operations well beyond these key data points.
With multiple updates expected, its analysts believe there is potential for momentum to build as the year progresses.
In afternoon trading, the stock was up 3.5% at 10p.